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Recently a large multicentre randomised controlled trial in
critically ill patients reported harm to the patients given
supplementary glutamine. In the original publication, no
explanation was offered for why this result was obtained; a
large number of studies have reported beneficial effects or
no effect, but never before reported harm. These results have
been commented upon in a number of communications.
Now some of the authors of the multicentre randomised
controlled trial present a review and meta-analysis of
glutamine supplementation, and the discrepancy of results
is suggested to relate to intravenous administration to
patients of supplementary glutamine via parenteral nutrition
or a combination of enteral and parenteral nutrition in
contrast to enteral administration of supplementation or a
combination of enteral and parenteral supplementation. To
explain results by epidemiological means only, by combining
results into a meta-analysis, is perhaps not the best way to
explain mechanisms behind results. Meta-analyses are primarily
hypothesis generating. Launching treatment without a solid
mechanistic explanation is always risky. Glutamine
supplementation of the critically ill comes into that category.
Now we will all have to do our homework and try to
understand whether supplementation or omission of
glutamine for patients fed parenterally is a good idea or not.Recently in Critical Care the REDOXS authors them-
selves published a meta-analysis confined to studiesThe authors of a multicentre randomised controlled trial
have recently presented a review and meta-analysis of
glutamine supplementation [1]. A discrepancy in results
is suggested to relate to intravenous administration to pa-
tients of supplementary glutamine via parenteral nutrition
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2014Supplementation of glutamine to critically ill patients
was suggested as level A or level B in most nutrition guide-
lines [2], but after the Reducing Deaths due to Oxidative
Stress (REDOXS) study there is a lot of confusion. In the
conclusion to their study, the REDOXS authors state that
‘early administration of glutamine in critically ill patients
with multiple organ failure was harmful. The observation
that the majority of these patients did not have glutamine
deficiency early in the course of their critical illness chal-
lenges the prevailing concept that glutamine is an essential
nutrient that is deficient in critically ill patients and re-
quires immediate supplementation’ [3]. Several studies
have shown that a low glutamine concentration, associated
with an unfavourable outcome, is valid for some 30% of
ICU patients [4,5]. Comments on the REDOXS study
interpretations vary widely – from ‘… should be abandoned
in clinical practice’ [6] to ‘… should be reserved for specif-
ically identified patients with compromised glutamine
availability’ [7].
There are also comments trying to analyse the
REDOXS study results in terms of unbalanced amino
acid composition [8] and bias in patient recruitment
[9]. Several comments are made after the use of
meta-analyses; such as reports that the beneficial ef-
fects of glutamine supplementation are confined to
single-centre studies [10] or to surgical patients [11].
with intravenous glutamine supplementation (thereby
excluding their own REDOXS study, which provided
glutamine supplementation both by enteral and parenteral
routes). The conclusion put forward is that ‘Parenteral
glutamine supplementation given in conjunction with
nutrition support continues to be associated with a
significant reduction in hospital mortality and hospital
length of stay. Parenteral glutamine supplementation
as a component of nutrition support should continue
to be considered to improve outcomes in critically ill
patients’ [1].Ltd. The licensee has exclusive rights to distribute this article, in any medium, for
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studies differently, thereby reaching different conclu-
sions. It is important always to remember the limita-
tions of meta-analyses, and to always remember that
they are primarily hypothesis generating – in particu-
lar when the treatment is variable in dose, in timing,
and in mode of administration, as is the case for sup-
plementary glutamine. There is a giant step from the
literature regarding glutamine deficiency in subgroups
of critically ill patients as a possible indication for
supplementation to outcome studies in unselected
groups of critically ill patients. As pointed out, the
use of meta-analyses to generate the hypothesis of
high-dose glutamine supplementation as a treatment
modality was perhaps to rush ahead of solid evidence
[12]. The scientific community now has to address
the task to explain the REDOXS study results. Is glutam-
ine supplementation harmful, is it a complete waste, or
might it be relevant in subgroups of patients?
The merit of the meta-analysis by Wischmeyer and
colleagues is that it points out the absence of indications
of harm in the studies included, and that potential
patient benefits are identified [1]. What is now needed is
a thorough search for a possible dose–response relation-
ship in conjunction with glutamine supplementation.
Are patients with a low plasma glutamine level at ICU
admission candidates for treatment? Should glutamine
be given regardless of nutrition support, or as a part of
nutrition support? What is proper dosing? The use of
meta-analyses to titrate dosing without any measure-
ments of admission glutamine status or post-treatment
glutamine status is not good science. Obviously, all of us
who have been involved in the glutamine story have to
do our homework much better. The first step must be to
explore the possible mechanisms by which a glutamine
deficiency may be harmful in some patients.
From the REDOXS study itself it is possible to hypothe-
sise from the small subgroup in which glutamine status was
actually studied that the toxic effects were not obviously
linked to supraphysiologic plasma levels [3]. This hypoth-
esis shifts the focus to the provision of large enteral doses
of glutamine, without proper feeding simultaneously. Bene-
ficial effects of large enteral doses together with feeding
have been demonstrated by others [13]. One must note,
however, that the first-pass elimination of enterally admin-
istered glutamine is very high [14,15]. The metabolic fate of
supplemented glutamine therefore seems to be different re-
lated to the route of administration and related to whether
glutamine is given as part of full nutrition or not. These
basic metabolic tasks must be addressed before any clinical
recommendations are given. To just abandon glutamine
without doing this homework properly will not be the best
service to our patients. There are too many observations of
beneficial effects to just throw glutamine away, and it is justa little too difficult to understand the toxicity of a substance
without high plasma levels.
In conclusion, the REDOXS study raises more question
than it answers. Studies addressing the underlying mechanisms
are needed to determine why glutamine may be toxic with-
out an increase in plasma concentration. Meta-analysis is
not the proper method to investigate underlying mecha-
nisms, and also not the proper way to launch clinical
recommendations. At best, meta-analysis may serve as
hypothesis generating. Following the REDOXS study we
all have to do our homework and try to understand the
role of glutamine in critical illness, and as a consequence
the possible indications and hazards associated with
supplementation.
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